Document Detail

Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
MedLine Citation:
PMID:  11191005     Owner:  NLM     Status:  MEDLINE    
A number of studies have shown that hyperuricaemia is associated with an increased incidence of coronary heart disease. It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes. Hyperuricaemia is commonly encountered in patients with essential hypertension and is considered as a risk factor for morbidity and mortality associated with hypertension. In addition, lipid abnormalities (mainly hypertriglyceridaemia) are also found more frequently in hypertensive patients than in normotensives. There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule. It is also known that fibric acid derivatives (fibrates) have several beneficial actions in addition to their lipid-lowering capacity. Fenofibrate administration is associated with a uric acid lowering effect. In this respect, we present two patients with hypertension and dyslipidaemia together with elevated serum uric acid levels. We also discuss (in the format of questions and answers) the pathophysiological mechanisms underlying the association of serum uric acid with cardiovascular disease, and we review the relevant literature to justify an evidence-based decision to choose an antihypetensive agent (losartan) or a lipid-lowering drug (fenofibrate) with an additional hypouricaemic effect.
H J Milionis; M S Elisaf
Related Documents :
9916555 - Age-related plasma chemistry findings in the buff-crested bustard (eupodotis ruficrista...
16705445 - The relationship between uric acid and its oxidative product allantoin: a potential ind...
5450375 - Allopurinol: alteration in pyrimidine metabolism in man.
12669155 - Characteristics of nanobacteria and their possible role in stone formation.
11491525 - Mycolic acids from mycobacterium tuberculosis: purification by countercurrent distribut...
15760185 - Shape-complementarity in the recognition of tricarboxylic acids by a [3+3] polyazacyclo...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Current medical research and opinion     Volume:  16     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2000  
Date Detail:
Created Date:  2001-01-16     Completed Date:  2001-03-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  164-70     Citation Subset:  IM    
Department of Internal Medicine, Medical School, University of Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / adverse effects*
Antilipemic Agents / therapeutic use
Arteriosclerosis / blood,  epidemiology
Hyperlipidemias / blood,  drug therapy*
Hypertension / blood,  drug therapy*
Losartan / adverse effects
Middle Aged
Procetofen / therapeutic use
Risk Factors
Sodium Chloride Symporter Inhibitors / adverse effects
Uric Acid / blood*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Antilipemic Agents; 0/Benzothiadiazines; 0/Diuretics; 0/Sodium Chloride Symporter Inhibitors; 114798-26-4/Losartan; 49562-28-9/Procetofen; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergi...
Next Document:  Marked effect of octreotide acetate in a case of pancreatic pleural effusion.